Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The oxazolidinones as a new family of antimicrobial agent
Autore:
Marchese, A; Schito, GC;
Indirizzi:
Inst Microbiol, I-16132 Genoa, Italy Inst Microbiol Genoa Italy I-16132Inst Microbiol, I-16132 Genoa, Italy
Titolo Testata:
CLINICAL MICROBIOLOGY AND INFECTION
, volume: 7, anno: 2001, supplemento:, 4
pagine: 66 - 74
SICI:
1198-743X(2001)7:<66:TOAANF>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
IN-VITRO ACTIVITIES; RESISTANT ENTEROCOCCUS-FAECIUM; STAPHYLOCOCCUS-AUREUS; QUINUPRISTIN-DALFOPRISTIN; EPEREZOLID PNU-100592; BACTERIAL-INFECTIONS; LINEZOLID PNU-100766; PENICILLIN-RESISTANT; ANTIBACTERIAL AGENTS; VANCOMYCIN;
Keywords:
oxazolidanone; linezolid; in vitro activity; in vivo activity;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
92
Recensione:
Indirizzi per estratti:
Indirizzo: Marchese, A Inst Microbiol, Largo R Benzi 10, I-16132 Genoa, Italy Inst Microbiol Largo R Benzi 10 Genoa Italy I-16132 oa, Italy
Citazione:
A. Marchese e G.C. Schito, "The oxazolidinones as a new family of antimicrobial agent", CL MICRO IN, 7, 2001, pp. 66-74

Abstract

The oxazolidinones are a new chemical class of synthetic antimicrobials characterized by a unique mechanism of protein synthesis inhibition. Linezolid is the first compound of this class and has recently received approval for the treatment of community- and hospital-acquired pneumonia and skin and skin structure infections. In vitro tests demonstrate that linezolid possesses a significant activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VR-E), vancomycin-intermediate strains (VISA) and penicillin-resistantpneumococci (PRPN). Combined with other drugs linezolid interacts favourably against many important pathogens and it is able to affect some bacterialvirulence factors as well as produce a postantibiotic effect. Results from experimental models of infection reveal linezolid to be highly active in vivo against infections due to Gram-positive pathogens. Linezolid may be administered either intravenously or orally with. oral bioavailability of approximately 100% and limited adverse effects. The clinical efficacy of linezolid has been investigated in several phase II and III trials. Linezolid has been proved to be useful in severe infections sustained by multiresistant Gram-positive microorganisms. Synthesis of the second-generation oxazolidinones with improved potency against Gram-positive and negative bacteria is currently under way.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 07:24:22